Proceedings of the Texas A&M Medical Student Grand Rounds

Prevalence of Vaccine Induced Maternally Derived SARS-CoV-2 Antibodies in Neonates

August 3, 2021 Sydney Nobles

Sydney Nobles

Introduction The Severe Acute Respiratory Syndrome Corona Virus 2, or SARS-CoV-2, is transmitted via nasal passages by respiratory droplets, and infects pulmonary cells by binding to their angiotensin- converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) receptors1. Spike protein is the specific glycoprotein on the virus that mediates entry into host cell binding ACE2 and TMPRSS22. Type II Alveolar Cells, the cells found in the lung that secrete pulmonary surfactant, seem to be a main cell target, or tropism of SARS-CoV-22. Two vaccines against SARS-CoV-2 were authorized by the FDA for emergency use in December of 2020. As of May 23, 2021, 1.65 billion doses have been distributed worldwide, with 284 million of those doses being distributed in the United States3. Methods A study investigated levels of ACE2 and TMPRSS2 placental tissue throughout gestation4. Another study measured maternal serum and cord blood for SARS-CoV-2 anti-spike and anti-receptor binding domain immunoglobulins in both post vaccination and post natural SARS-CoV-2 infection5. SARS-CoV-2 immunoglobulins were also measured in breastmilk of lactating women1. Results Statically significant (p < 0.0011) increases were seen in SARS-CoV-2 antibodies in vaccinated pregnant women compared to naturally infected pregnant women1. The placental transfer ratio of anti-Spike IgG and anti-Receptor Binding Domain specific IgG were 0.44 and 0.24, respectivly5. Levels of vaccine mediated IgA SARS-Cov-2 antibodies in breastmilk were lower in a vaccine response compared to natural infections1. Conclusions Studies have found that the SARS-CoV-2 vaccine elicits a higher antibody response than a natural infection, which is important since fetal levels of maternally derived SARS-CoV-2 antibodies are directly correlated to the maternal levels1. However, the placental transfer ratio was found to be lower than other standard gestational vaccines5. This suggests that there is an optimal time for the vaccination during gestation, to maximize the placental transfer ratio5. IgG SARS-Cov-2 antibodies were the predominant antibody seen in breastmilk in lactating women after the COVID-19 vaccine, whereas IgA SARS-Cov-2 antibodies are predominant in breastmilk after a natural infectiong1. This difference is thought to be due to a natural infection eliciting a mucosal initiated immune response due to the virus being transmitted through droplets while the vaccine elicits an intramuscular initiated immune response1.

  1. Gray KJ, Bordt EA, Atyeo C, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. Published online March 26, 2021. doi:10.1016/j.ajog.2021.03.023
  2. Fenizia C, Biasin M, Cetin I, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nat Commun. 2020;11(1):5128. doi:10.1038/s41467-020-18933-4
  3. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed March 2, 2021. https://covid.cdc.gov/covid-data-tracker
  4. Wastnedge EAN, Reynolds RM, van Boeckel SR, et al. Pregnancy and COVID-19. Physiol Rev. 2021;101(1):303-318. doi:10.1152/physrev.00024.2020
  5. Shen C, Xu H, Liu D, Veazey RS, Wang X. Development of serum antibodies during early infancy in rhesus macaques: implications for humoral immune responses to vaccination at birth. Vaccine. 2014;32(41):5337-5342. doi:10.1016/j.vaccine.2014.07.036
Microbiology
Previous Post

Allosteric Modulation of Metabotropic Glutamate Receptors as a Therapeutic Mechanism for Schizophrenia

Next Post

Estrogen Receptors in the Regulation of Castration-Resistant Prostate Cancer

Scientific Editors

Steve A. Maxwell

Executive Editor
Tel: 979-436-0804
smaxwell@medicine.tamhsc.edu

Robin Fuchs-Young

Deputy Editor
Tel: 979-845-5109
fuchs-young@medicine.tamhsc.edu
Administrative Editor

Janis Chmiel

Tel: 979-436-0856
chmiel@medicine.tamhsc.edu
Editorial Office
Tel.: 979-845-2726
Fax: 979-847-9481
chmiel@medicine.tamhsc.edu
Archives
  • July 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • May 2025
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • November 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • August 2022
  • June 2022
  • May 2022
  • August 2021
  • July 2021
  • April 2021
  • October 2020
  • August 2020
  • July 2020
  • August 2019
  • July 2019
  • February 2019
  • July 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • January 2017
Proudly powered by WordPress | Theme: Fmi by Forrss.